ISSN Print 2500–1094
ISSN Online 2542–1204
BIOMEDICAL JOURNAL OF PIROGOV UNIVERSITY (MOSCOW, RUSSIA)
ORIGINAL RESEARCH
Analysis of the polymorphic variants of ADRB2 gene association with the β2-agonists response in patients with a rare theratype of asthma
About authors
National Research Center Institute of Immunology of the Federal Medical-Biological Agency, Moscow, Russia
Correspondence should be addressed: Ksenia S. Pavlova
Kashirskoe shosse, 24, Moscow, 115522; moc.liamg@lacideminesk
About paper
Funding: the study was supported by the Russian Foundation for Basic Research as part of the Project #19-33-90076.
Acknowledgement: we would like to thank the Biomedicine Center for High-Precision Editing and Genetic Technologies of Pirogov Russian National Research Medical University (Moscow, Russia) for access to the molecular genetics systems.
Author contribution: Mdinaradze DS, Pavlova KS, Kurbacheva OM — selection of patients, clinical laboratory and instrumental examinations, collection of biological material; Kozlov IB, Kofiadi IA — development of the new PCR test system for analysis of the ADRB2 gene polymorphic variants, genetic testing execution.
Compliance with ethical standards: the study was approved by the ethics committee of the Institute of Immunology of the Federal Medical-Biological Agency (Minutes #13 of October 16, 2017); all patients signed voluntary consent to participate in the study.
Received: 2020-11-25
Accepted: 2020-12-09
Published online: 2020-12-27
|
Fig. 1. The results of sequencing of homozygous and heterozygous samples. The varying nucleotides are shown in gray. Peculiar to the homozygotes is a single peak in the chromatogram at the position of the rs1042713 and 1042714 polymorphisms (A and C, respectively). Heterozygotes are characterized by a double peak at the position of the rs1042713 and 1042714 polymorphisms (B and D, respectively)
Table. Distribution of the allele and genotype frequencies of ADRB2 gene's rs1042713 (Arg16Gly) and rs1042714 (Gln27Glu) polymorphisms in asthma patients with various theratypes (SABA+SAMA+ — patients with clinically and instrumentally confirmed positive response to salbutamol)
